NCT05935774View on ClinicalTrials.gov

OT-101 in Combination With Atezolizumab for the Treatment of Metastatic or Recurrent Non-Small Cell Lung Cancer

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

December 1, 2023

Primary Completion Date

July 31, 2028

Study Completion Date

July 31, 2028

Conditions
Metastatic Lung Non-Small Cell CarcinomaRecurrent Lung Non-Small Cell CarcinomaStage IV Lung Cancer AJCC v8
Interventions
BIOLOGICAL

Atezolizumab

Given IV

PROCEDURE

Biopsy

Undergo biopsy

PROCEDURE

Biospecimen Collection

Undergo blood sample collection

PROCEDURE

Computed Tomography

Undergo CT

OTHER

Electronic Health Record Review

Ancillary studies

PROCEDURE

Magnetic Resonance Imaging

Undergo MRI

DRUG

Trabedersen (OT-101)

Given IV

Trial Locations (1)

98109

Fred Hutch/University of Washington Cancer Consortium, Seattle

Sponsors
All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

collaborator

Oncotelic Therapeutics, Inc.

UNKNOWN

lead

University of Washington

OTHER

NCT05935774 - OT-101 in Combination With Atezolizumab for the Treatment of Metastatic or Recurrent Non-Small Cell Lung Cancer | Biotech Hunter | Biotech Hunter